ThermoGenesis Holdings, Inc

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, CAR-Txpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

ThermoGenesis (NASDAQ: THMO ) stock is taking a beating on Wednesday after the company announced an update on its listing compliance. According to a ThermoGenesis filing, it has received another delisting notice from the Nasdaq Exchange.

Why Is ThermoGenesis (THMO) Stock Down 37% Today?

ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Paula Schwartz - Rx Communications, IR Dr. Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day.

ThermoGenesis Holdings, Inc. (THMO) Q3 2023 Earnings Call Transcript

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m.

ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Conference Call to be Held on November 13, 2023 RANCHO CORDOVA, Calif. , Nov. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2023, and provide a corporate strategic update on Thursday, November 13, 2023, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide a Corporate Strategic Update

An ISO 7 cGMP Cleanroom Facility Grand Opening On October 26, 2023 RANCHO CORDOVA, Calif. , Oct. 26, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and cell and gene therapy services, announced the grand opening of its new state-of-the-art facility, housing ISO 7 cGMP cleanroom suites, along with research and development labs.

ThermoGenesis to Open a New 35,500 Square Foot ReadyStart-IncuStart cGMP Facility in Greater Sacramento

RANCHO CORDOVA, Calif. , Sept. 6, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D.

ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Thermogenesis Holdings, Inc. (NASDAQ:THMO ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Paula Schwartz - IR, Rx Communications Group Chris Xu - CEO Jeff Cauble - CFO Conference Call Participants Sean Lee - H.C. Wainwright & Co. Operator Good day, and welcome to the ThermoGenesis Holdings conference call and webcast to review financial and operating results for the second quarter ended June 30, 2023.

Thermogenesis Holdings, Inc. (THMO) Q2 2023 Earnings Call Transcript

ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Conference Call to be Held on August 10, 2023 RANCHO CORDOVA, Calif. , Aug. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the Second Quarter ended June 30, 2023 and Provide a Corporate Strategic Update

RANCHO CORDOVA, Calif. , July 17, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced the appointments of Biao Xi, Ph.D.

ThermoGenesis Expands Board of Directors with the Appointments of Dr. Biao Xi and Dr. James Xu

ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day, and welcome to the ThermoGenesis Holdings Conference Call and Webcast to review Financial and Operating Results for the First Quarter ended March 31, 2023.

ThermoGenesis Holdings, Inc. (THMO) Q1 2023 Earnings Call Transcript

ThermoGenesis Holdings Announces First Quarter 2023 Financial Results and Provides Corporate Update

Conference Call to be Held on May 15, 2023 RANCHO CORDOVA, Calif. , May 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 and provide a corporate strategic update on Monday, May 15, 2023, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide a Corporate Strategic Update

ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day, and welcome to the ThermoGenesis Holdings Conference Call Webcast to review Financial and Operating Results for the Year Ended December 31, 2022.

ThermoGenesis Holdings, Inc. (THMO) Q4 2022 Earnings Call Transcript

ThermoGenesis Holdings Announces Year End 2022 Financial Results and Provides Corporate Update

Conference Call to be Held on March 30, 2023 RANCHO CORDOVA, Calif. , March 28, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the Year Ended December 31, 2022 and Provide a Corporate Strategic Update

RANCHO CORDOVA, Calif. , March 20, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced the closing of its previously announced purchase and sale of 1,071,429 shares of its common stock (or common stock equivalents) and warrants to purchase up to 1,071,429 shares of its common stock at a purchase price of $2.80 per share of common stock (or common stock equivalent) and associated warrant in a private placement priced at-the-market under Nasdaq rules.

THERMOGENESIS CLOSES $3 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

RANCHO CORDOVA, Calif. , March 16, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has entered into definitive agreements for the purchase and sale of 1,071,429 shares of its common stock (or common stock equivalents) and warrants to purchase 1,071,429 shares of its common stock at a purchase price of $2.80 per share of common stock (or common stock equivalent) and associated warrant in a private placement priced at-the-market under Nasdaq rules.

THERMOGENESIS ANNOUNCES $3 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

ThermoGenesis (NASDAQ: THMO ) stock is rocketing higher on Thursday after the company announced new cGMP Suites. These cGMP Suites are for early-stage life science and cell gene therapy companies.

Why Is ThermoGenesis (THMO) Stock Up 54% Today?

ThermoGenesis said it plans to rent out its current Good Manufacturing Practices suites in the second and third quarters. The company was nearly delisted from the Nasdaq last year.

Why ThermoGenesis Stock Is Soaring Wednesday

What's causing ThermoGenesis Holdings (NASDAQ: THMO ) stock traders to suddenly go on a buying binge? Evidently, the share-price rally is prompted by ThermoGenesis's announcement that it's launching a new facility in the Sacramento metro area of California.

THMO Stock Alert: Why ThermoGenesis Is Up 95% Today

RANCHO CORDOVA, Calif. , March 15, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company is rolling out a new facility in the Sacramento metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease by early-stage life science and cell gene therapy ("CGT") companies.

ThermoGenesis Announces Roll Out of ReadyStart cGMP Suites for Early-Stage Cell and Gene Therapy Companies

RANCHO CORDOVA, Calif. , Jan. 11, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) ("Min Bid Price Rule").

ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement

RANCHO CORDOVA, Calif. , Dec. 21, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced a 1-for-45 reverse stock split of its outstanding common stock, effective at 12:01 a.m.

ThermoGenesis Announces 1-for-45 Reverse Stock Split

ContraFect

Eargo

Penny stocks to buy for under $1 but are they worth the risk? The post 3 Hot Penny Stocks To Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for ThermoGenesis Holdings, Inc Stock (THMO)